<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55006657"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<reference>CLIN. CHEM. 34/9, 1781-1 786 (1988)<lb/> CLINICAL CHEMISTRY, Vol. 34, No. 9, 1988 </reference>
	
	<note type="page">1781<lb/></note>

	<docTitle>
	<titlePart>High-Density Lipoprotein Apolipoproteins in Urine: II. Enzyme-Linked<lb/> Immunoassay of<lb/> Apolipoprotein A-I<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>Zvenyika A. R. Gomo1 and L Omar Henderson2<lb/></docAuthor>
	</byline>

	<div type="abstract">We have developed<lb/> a capture<lb/> antibody,<lb/> noncompetitive,<lb/> enzyme-linked<lb/> immunoassay for urinary apolipoprotein<lb/> A-I<lb/> (Apo A-I) in urine, with use of affinity-purified<lb/> polyclonal antisera against Apo A-I. A 96-well microtiter plate format is<lb/> used, with unconcentrated<lb/> urine as sample and dilutions of<lb/> serum or high-density<lb/> lipoprotein (HDL) as standards.<lb/> The intra-and interassay<lb/> variation (CV) averaged<lb/> 7.4% and<lb/> 9.4%,<lb/> respectively.<lb/> The limit of detection<lb/> is low (1.25 ng/L),<lb/> and no cross-reactivity<lb/> with Apo B, C, E, or A-li was detected.<lb/> The mean (±SD)<lb/> concentrations of Apo A-I in urine of<lb/> patients with glomerular<lb/> proteinuria were a thousandfold<lb/> greater (38.4 ± 23.1 mg/L) than in normal subjects (16.3 ±<lb/> 11.3 p.g/L in men, 17.97 ± 7.7 g/L<lb/> in women, a significant<lb/> difference,<lb/> P &lt;0.001).<lb/> Apo A-I measurements<lb/> correlated very well (r = 0.92) with selectivity<lb/> index assessment.<lb/> The diurnal variation<lb/> of the concentration<lb/> of Apo A-I in urine<lb/> appears to result from dilution related to fluid intake. This<lb/> enzymatic method is easy to perform, can be used with large<lb/> numbers</div>

		</front>
	</text>
</tei>
